Candel Therapeutics Unveils Promising CAN-2409 Findings
At the recent Annual Meeting of the American Society for Radiation Oncology (ASTRO), Candel Therapeutics, Inc. (NASDAQ: CADL) showcased the results from a landmark phase 3 clinical trial investigating CAN-2409 (aglatimagene besadenovec) in localized prostate cancer. This clinical-stage biopharmaceutical company is dedicated to developing innovative therapies that empower patients in their fight against cancer. The findings presented at ASTRO reflect a significant advancement in treatment for patients diagnosed with intermediate-to-high-risk localized prostate cancer.
Trial Insights and Significant Findings
The phase 3 clinical trial conducted by Candel aimed to address a pressing issue in cancer treatment: disease recurrence. Despite established radiation therapies, around 30% of patients continue to face recurrence within a decade. The insights presented revealed that those receiving CAN-2409 alongside standard radiation therapy fared significantly better than those who received a placebo. The results showed a commendable 30% improvement in disease-free survival, along with a remarkable 38% enhancement in prostate cancer-specific disease-free survival, highlighting CAN-2409's potential effectiveness.
Study Design and Results
In this trial, 745 participants with localized prostate cancer were randomly allocated in a 2:1 ratio to receive either CAN-2409 combined with valacyclovir or standard care. Patients were treated with the new biopharmaceutical before and during their radiation sessions. Key findings from the subgroup analysis illustrated that CAN-2409’s benefits were consistent across various radiation modalities, making it a versatile treatment option for clinicians and patients alike.
At the two-year mark, a notable 80.4% of patients demonstrated a pathological complete response compared to 63.6% in the control group, emphasizing the potential breakthrough CAN-2409 represents in the fight against localized prostate cancer.
Key Highlights from ASTRO Presentations
The presentation at ASTRO highlighted several critical findings:
- CAN-2409 markedly improved prostate cancer-specific outcomes (HR 0.62; p=0.0046) across different forms of radiation therapy.
- The treatment showed durability and safety, with a considerable number of patients undergoing either conventional radiation therapy or moderate hypofractionated radiation therapy reporting similar tolerability.
- Adverse events related to the treatment were notably low, indicating CAN-2409's manageable safety profile.
Expert Opinions on the Findings
Glen Gejerman, M.D., M.B.A., Co-Director of Urologic Oncology, shared his insights, stating, “The analyses indicate that CAN-2409's efficacy is independent of the radiation modality, providing hope for patients utilizing moderate hypofractionated radiation due to its convenience.”
Further reinforcing the treatment's potential, Paul Peter Tak, M.D., Ph.D., CEO of Candel, emphasized the significance of these findings: “Our results point to CAN-2409's broad therapeutic potential. The consistent performance across different treatment modalities aligns with our vision to bring groundbreaking treatments to those battling localized prostate cancer.”
Understanding CAN-2409
CAN-2409 is Candel’s leading investigational therapy, developed as a unique biological immunotherapy candidate. Utilizing a specially engineered adenovirus, CAN-2409 aims to promote targeted tumor destruction by transforming a prodrug into an active agent within the tumor environment, effectively inducing a strong immune response.
This innovative approach is designed not only to attack the primary tumor but also to activate an immunogenic response against potential distant metastases, offering hope for comprehensive cancer control. Encouraging results have been noted in various preclinical and clinical contexts, setting the groundwork for CAN-2409 to potentially bridge into broader cancer treatment avenues.
About Candel Therapeutics
Candel Therapeutics, Inc. is at the forefront of biopharmaceutical innovation, focusing on multimodal therapies that can empower patients fighting complex cancer challenges. Following successful phase 2a trials, Candel has established itself as a pivotal player in the industry by exploring the therapeutic landscape with promising candidates like CAN-2409 and CAN-3110, each tailored to make significant impacts on treatment paradigms for various cancer types.
The company is dedicated to developing off-the-shelf solutions that facilitate a tailored immune response—essentially seeking to revolutionize cancer treatment through personalized medicine.
Frequently Asked Questions
What is CAN-2409?
CAN-2409 is an investigational biological immunotherapy candidate developed by Candel Therapeutics designed to enhance the body’s immune response against localized prostate cancer.
What were the results of the phase 3 trial?
The phase 3 trial resulted in a 30% improvement in disease-free survival and a 38% enhancement in prostate cancer-specific outcomes for patients treated with CAN-2409.
What does Candel Therapeutics focus on?
Candel Therapeutics focuses on developing multimodal biological immunotherapies that harness the body’s immune system to target and eliminate cancer cells.
What is the significance of the ASTRO presentation?
The ASTRO presentation underscored the promising efficacy and safety profile of CAN-2409 across various radiation treatment modalities, potentially marking a shift in localized prostate cancer management.
When is the Biologics License Application submission expected?
Candel Therapeutics anticipates submitting the Biologics License Application for CAN-2409 in the fourth quarter of 2026.
